Eileen P. Smith, M.D.

[email protected]
(877) 460-4673
Eileen P. Smith, M.D.
Hematologist
Clinical Expertise
  • Hematology-Oncology
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Leukemia
Academic Appointments
  • Professor, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Acute Myeloid Leukemia
Bone Marrow and Stem Cell Transplantation
Leukemia
Myelodysplastic Syndrome
Myeloma and Multiple Myeloma
Hematology & Hematopoietic Cell Transplantation
Research Teams
Alpha Stem Cell Therapies
Hematology & Hematopoietic Cell Transplantation
Eileen P. Smith, M.D., has spent nearly three decades at City of Hope, beginning in 1988 as a fellow in medical oncology and bone marrow transplantation.
 
A respected specialist in the field, Dr. Smith is a professor of City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation.
 
She is currently running a clinical trial examining the effectiveness of administering a double or “tandem” dose of a patient's own healthy stem cells within a relatively short period of time.
 
Dr. Smith received her medical degree from University of Southern California where she also did a fellowship in hematology. She served in the National Health Service Corps, and is active in PRIM&R: Public Responsibility in Medicine & Research.

Location

Education & Experience

Board Certifications

  • 1989, Diplomate, ABIM Subspecialty of Medical Oncology
  • 1988, Diplomate, ABIM Subspecialty of Hematology
  • 1984, Diplomate, American Board of Internal Medicine
  • 1982, Diplomate, National Board of Medical Examiners

Degrees

  • 1981, University of Southern California School of Medicine, Los Angeles, CA, M.D.
  • 1976, Fairfield University, Fairfield, CT, B.S. Cum Laude, Biology

Fellowship

  • 1988-1989, Fellowship in medical oncology/bone marrow transplantation, City of Hope, Duarte, CA
  • 1986-1988, Fellowship in hematology, Los Angeles County+USC Medical Center, Los Angeles, CA

Residency

  • 1981-1984, Internship and residency, Harbor-UCLA Medical Center, Torrance, CA

Professional Experience

  • 2003-present, Staff Physician and Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2019-2026, Professor, Francis & Kathleen McNamara Distinguished Chair in Hematology & Hematopoietic Transplantation, City of Hope, Duarte, CA
  • 2013-2026, Chair, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 1996-2003, Associate Professor of Medicine, Department of Medicine, University of Wisconsin Medical School, Madison, WI
  • 1994 - 1996, Clinical Assistant Professor of Family Medicine & Medicine, Los Angeles, CA
  • 1988-1996, Staff Physician, Department of Hematology & Hematopoietic Cell Transplantation, Duarte, CA
  • 1984-1986, National Health Service Corps: Physician Specialist in Adult Medicine, Los Angeles, CA

Awards & Memberships

Awards

  • 2020, Los Angeles Business Journal, Top Women Leaders

Memberships

  • 2006-present, Public Responsibility in Medicine and Research

  • 2003-present, Southwest Oncology Group

  • 1998-present, American Society of Clinical Oncology

  • 1997-2003, Eastern Cooperative Oncology Group

  • 1994-present, American Society for Blood & Marrow Transplantation

  • 1996-1996, Southwest Oncology Group

  • 1977, American Society of Hematology

Publications

  • Chen R, Palmer JM, Popplewell L, Shen J, Smith E, Delioukina M, Kogut N, Rosenthal J, Forman S, Nademanee A. Reduced intensity allogeneic Hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol. 2011 Jul;90(7):803-8.
  • Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, Forman SJ, Lievers E, Thomas SH, and Chen RW. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012 Oct;53(10):2051-3.
  • Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, and Stiff PJ. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707 Epub 2017 Dec. 28. PMID: 29289757; PMCID: PMC5965270
  • Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MR, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, and Nakamura R. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 Sep;24(9):1828-1835. PMID: 29753158; PMCID: PMC6163069
  • Wolfson JA, Richman JS, Sun CL, Landier W, Leung K, Smith EP, O’Donnell M, Bhatia S. Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1133-1141. DOI: 10.1158/1055-9965.epi-18-0430. PMID:30262597 PMCID: PMC6238217
  • Dadwal SS, Al Malki MM, Yang D, Tegtmeier BR, Ross J, Mokhtari S, Marcucci G, Palmer J, Salhotra A, Dickter J, O’Donnell MR, Smith E, Karanes C, Snyder DS, Mei M, Pullarkat V, Aldoss I, Stein AS, Sandhu KS, Spielberger R, Nademanee A, Ito JI, Forman SJ, Zaia JA, Nakamura R. Real World Experience of Letermovir (LTV) Prophylaxis (px) for the Prevention of Cytomegalovirus Infection (CMV) in the Adult CMV Seropositive Recipients (R plus) of Allogeneic Hematopoietic Cell Transplantation (HCT) Patients (pts). Biology of Blood and Marrow Transplantation. 2019:25(3):2.
  • Dulan SO, Viers KL, Wagner JR, Clark MC, Chang B, Gorospe GL, Londrc A, Brown AS, Rosenthal J, Smith EP, Forman SJ, Snyder DS, Budde LE. Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. Biol Blood Marrow Transplant. 2020 Aug;26(8):1386-1393. doi: 10.1016/j.bbmt.2020.03.021. Epub 2020 May 19. PMID:32439475
  • Mei M, Tsai NC, Mokhtari s, Al Malki MM, Ali H, Salhotra A, Sandhu K, Khaled S, Smith E, Snyder D, Marcucci G, Forman SJ, Pullarkat V, Stein A, Aldoss I, Nakamura R. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-vs-Host Disease prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2020 Aug:26(8):1425-1432. doi:10.1016/j.bbmt.2020.04.015. Epub 2020 May 19. PMID: 32416253
  • Herrera AF, Palmer JP, Adhikarla V, Yamauchi DM, Poku EK, Bading J, Yazaki Paul, Dandapani S, Mei MG, Chen RW, Cao T, Karras NA, McTague P, Nademanee A, Popplewell L, Sahebi F, Shively JE, Simpson JR, Smith DL, Song J, Spielberger R, Tsai NC, Thomas SH, Forman SJ, Colcher D, Wu AM, Wong JY, Smith EP. Anti-CD25 Radioimmunotherapy with BEAM Autologous Hematopoietic Cell Transplantation Conditioning in Hodgkin Lymphoma. Blood Adv. 2021 Oct. 12. Online ahead of print. PMID: 34638132
  • Kambhampati S, Mei MG, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Jun 6:S2152-2650(22)00185-9. doi: 10.1016/j.clml.2022.06.004. Epub ahead of print. PMID: 35778267.
  • Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
5.0
Rate provider 0-10
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Know important info medical history
4.9
Spend enough time with you
4.8
Provider listen carefully to you
03/23/26
Dr Eileen Smith is the Best professional and caring physician - Verified patient
11/03/25
Perfect & Excellent! - Verified patient
11/03/25
I love my provider so much she meets all my concerns & care Thanks Dr. Eillen S.! - Verified patient
04/22/25
Well recommended to all! - Verified patient
04/22/25
Best provider of all' - Verified patient